Your browser doesn't support javascript.
loading
Heart transplantation for COVID-19 myopathy in the United States.
Gill, George; Roach, Amy; Rowe, Georgina; Emerson, Dominic; Kobashigawa, Jon; Lobo, Errol P; Esmailian, Fardad; Bowdish, Michael E; Chikwe, Joanna.
Afiliação
  • Gill G; Department of Cardiac Surgery, Cedars-Sinai Medical Center, Los Angeles, CA.
  • Roach A; Department of Cardiac Surgery, Cedars-Sinai Medical Center, Los Angeles, CA.
  • Rowe G; Department of Cardiac Surgery, Cedars-Sinai Medical Center, Los Angeles, CA.
  • Emerson D; Department of Cardiac Surgery, Cedars-Sinai Medical Center, Los Angeles, CA.
  • Kobashigawa J; Department of Cardiology, Cedars-Sinai Medical Center, Los Angeles, CA.
  • Lobo EP; Department of Anesthesiology, Cedars-Sinai Medical Center, Los Angeles, CA.
  • Esmailian F; Department of Cardiac Surgery, Cedars-Sinai Medical Center, Los Angeles, CA.
  • Bowdish ME; Department of Cardiac Surgery, Cedars-Sinai Medical Center, Los Angeles, CA.
  • Chikwe J; Department of Cardiac Surgery, Cedars-Sinai Medical Center, Los Angeles, CA. Electronic address: Joanna.Chikwe@cshs.org.
J Heart Lung Transplant ; 42(4): 447-450, 2023 04.
Article em En | MEDLINE | ID: mdl-36682895
Evidence on characteristics and outcomes of patients undergoing heart transplantation for coronavirus disease 2019 (COVID-19) associated cardiomyopathy is limited to case reports. Of all 6,332 patients aged ≥18 years undergoing heart transplantation from July 2020 through May 2022 in the United Network for Organ Sharing database, 12 (0.2%) patients had COVID-19 myocarditis and 98 (1.6%) patients with the same level of care had non-COVID-19 myocarditis. Their median age was 49 (range 19-74) years. All patients were hospitalized in the intensive care unit and 92.7% (n = 102) were on life support prior to transplantation. No patients with COVID-19 myocarditis required ventilation while waitlisted. Survival free from graft failure was 100% among COVID-19 patients and 88.5% among non-COVID-19 patients at a median of 257 (range 0-427) days post-transplant. These findings indicate that transplantation is rarely performed for COVID-19 related cardiomyopathy in the United States, yet early outcomes appear favorable in select patients.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Transplante de Coração / COVID-19 / Cardiomiopatias Tipo de estudo: Etiology_studies Limite: Adult / Aged / Humans / Middle aged País/Região como assunto: America do norte Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Transplante de Coração / COVID-19 / Cardiomiopatias Tipo de estudo: Etiology_studies Limite: Adult / Aged / Humans / Middle aged País/Região como assunto: America do norte Idioma: En Ano de publicação: 2023 Tipo de documento: Article